Anthony S. Stein, M.D.
Hematologist-Oncologist
4.9 (78 RATINGS)
Clinical Expertise
Leukemia
Hematopoietic Stem Cell Transplantation
Research Area
Acute Leukemia
Myelodysplasia
Hematology and Hematopoietic Cell Transplantation
Appointments
Associate Director, Gehr Family Center for Leukemia Research
Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation
Clinical Teams
Acute Myeloid Leukemia
Hematology & Hematopoietic Cell Transplantation
Leukemia
Lymphoma
Myelodysplastic Syndrome
“Excellent care for patients” is the guiding principle for Anthony S. Stein, M.D., a member of the City of Hope team since 1985. Dr. Stein is a professor and physician in the Department of Hematology & Hematopoietic Cell Transplantation and associate director of the Gehr Family Center for Leukemia Research within the Hematologic Malignancies Research Institute.
Educated in South Africa, Dr. Stein received his medical degree from the University of Cape Town. He completed his residency at Montefiore Medical Center in Pittsburgh before joining City of Hope as a fellow in hematology/oncology.
Dr. Stein is principal investigator in multiple clinical trials examining the newest drugs for battling acute myeloid leukemia and acute lymphoid leukemia and hematopoietic stem cell transplantation.
Duarte - Main Campus
1500 East Duarte Road
Duarte, CA 91010
Duarte, CA 91010
1978, University of Cape Town Medical School, Cape Town, South Africa, M.B., Ch, B.
1985-1988, Fellowship, City of Hope, Duarte, CA, Hematology/Oncology
1982-1985, Residency, Department of Medicine, Internal Medicine, Montefiore Hospital, Pittsburgh, PA
1979, Internship (Rotating), Groote Schuur Hospital, Cape Town, South Africa
2016-present, Associate Director, Gehr Family Center for Leukemia Research, Hematologic Malignancies Research Institute, City of Hope, Duarte, CA
1988-present, Professor, Division of Leukemia, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2019, Top Consenting Physician for Therapeutic Studies - Cancer Center Executive Committee
Children's Oncology Group
American Society of Clinical Oncology
American Society of Hematology
Southwest Oncology Group
American Society for Blood and Marrow Transplantation
- WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens. Aribi, A., Salhotra, A., Afkhami, M., Munteanu, A., Ali, H., Aldoss, I., Otoukesh, S., Al Malki, M. M., Sandhu, K. S., Koller, P., Arslan, S., Stewart, F., Artz, A., Curtin, P., Ball, B., O'Hearn, J., Spielberger, R., Smith, E., Budde, E., Nakamura, R., … Pullarkat, V. (2023). Leukemia & lymphoma, 1–11. Advance online publication.
- Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma. Mei, M., Palmer, J., Tsai, N. N., Simpson, J., O'Hearn, J., Stein, A., Forman, S., Spielberger, R., Cai, J. L., Htut, M., Nakamura, R., Al Malki, M. M., Herrera, A., Wong, J., & Nademanee, A. (2023). Clinical lymphoma, myeloma & leukemia, 23(9), e268–e276.
- Tocilizumab for Cytokine Release Syndrome Management After Haploidentical Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis. Yao, J. M., Otoukesh, S., Kim, H., Yang, D., Mokhtari, S., Samara, Y., Blackmon, A., Arslan, S., Agrawal, V., Pourhassan, H., Amanam, I., Ball, B., Koller, P., Salhotra, A., Becker, P., Curtin, P., Artz, A., Aldoss, I., Ali, H., Stewart, F., … Al Malki, M. M. (2023).Transplantation and cellular therapy,29(8), 515.e1–515.e7.
- Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience. Amanam, I., Yao, J., Puing, A., Tsai, N. C., Samuels, D., Ngo, D., Ho, S., Ali, H., Aribi, A., Arslan, S., Artz, A., Htut, M., Koller, P., Salhotra, A., Sandhu, K., Nikolaenko, L., Pawlowska, A., Shouse, G., Stein, A., Marcucci, G., … Al Malki, M. M. (2023). Cancer medicine,12(10), 11248–11253.
- Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study. La Rosa, C., Chiuppesi, F., Park, Y., Zhou, Q., Yang, D., Gendzekhadze, K., Ly, M., Li, J., Kaltcheva, T., Ortega Francisco, S., Gutierrez, M. A., Ali, H., Otoukesh, S., Amanam, I., Salhotra, A., Pullarkat, V. A., Aldoss, I., Rosenzweig, M., Aribi, A. M., Stein, A. S., … Diamond, D. J. (2023). Frontiers in immunology,14, 1114131.
- High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia-like fusions. Aldoss, I., Afkhami, M., Yang, D., Gu, Z., Mokhtari, S., Shahani, S., Pourhassan, H., Agrawal, V., Koller, P., Arslan, S., Tomasian, V., Al Malki, M. M., Artz, A., Salhotra, A., Ali, H., Aribi, A., Sandhu, K. S., Ball, B., Otoukesh, S., Amanam, I., … Pullarkat, V. (2023). American journal of hematology,98(6), 848–856.
- Report of four acute myeloid leukemia patients with sustained complete remission with less frequent administration of decitabine and venetoclax. Aribi, A., Salhotra, A., Ball, B., Stein, A., Marcucci, G., & Pullarkat, V. (2023). Leukemia & lymphoma,64(4), 897–899.
- Low leukemia burden improves blinatumomab efficacy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Queudeville, M., Stein, A. S., Locatelli, F., Ebinger, M., Handgretinger, R., Gökbuget, N., Gore, L., Zeng, Y., Gokani, P., Zugmaier, G., & Kantarjian, H. M. (2023). Cancer,129(9), 1384–1393.
- Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab. Agrawal, V., Pourhassan, H., Tsai, N. C., Ngo, D., Koller, P., Malki, M. M. A., Salhotra, A., Ali, H., Aribi, A., Sandhu, K. S., Arslan, S., Ball, B., Otoukesh, S., Amanam, I., Artz, A., Singh, D., Becker, P. S., Stewart, F. M., Smith, E. P., Curtin, P., … Aldoss, I. (2023). Transplantation and cellular therapy,29(5), 314–320.
- Long-term follow up of patients with hematological malignancies treated with total body irradiation using intensity modulated radiation therapy. Ladbury, C., Hao, C., Yang, D., Hui, S., Han, C., Liu, A., Salhotra, A., Nakamura, R., Rosenthal, J., Stein, A., Wong, J., & Dandapani, S. (2022). Frontiers in oncology,12, 1044539.
- Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia. DiNardo CD, Stein AS, Stein EM, Fathi AT, Frankfurt O, Schuh AC, Döhner H, Martinelli G, Patel PA, Raffoux E, Tan P, Zeidan AM, de Botton S, Kantarjian HM, Stone RM, Frattini MG, Lersch F, Gong J, Gianolio DA, Zhang V, Franovic A, Fan B, Goldwasser M, Daigle S, Choe S, Wu B, Winkler T, Vyas P.J Clin Oncol. 2021 Jan 1;39(1):57-65. doi: 10.1200/JCO.20.01632. Epub 2020 Oct 29. PMID: 33119479
- Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia. Roboz GJ, DiNardo CD, Stein EM, de Botton S, Mims AS, Prince GT, Altman JK, Arellano ML, Donnellan W, Erba HP, Mannis GN, Pollyea DA, Stein AS, Uy GL, Watts JM, Fathi AT, Kantarjian HM, Tallman MS, Choe S, Dai D, Fan B, Wang H, Zhang V, Yen KE, Kapsalis SM, Hickman D, Liu H, Agresta SV, Wu B, Attar EC, Stone RM.Blood. 2020 Feb 13;135(7):463-471. doi: 10.1182/blood.2019002140. PMID: 31841594
- Venetoclax and hypomethylating agents in FLT3-mutated acute myeloid leukemia. Aldoss I, Zhang J, Mei M, Al Malki MM, Arslan S, Ngo D, Aribi A, Ali H, Sandhu K, Salhotra A, Koller P, Khaled S, Artz A, Snyder D, Nakamura R, Forman SJ, Stein AS, Marcucci G, Pullarkat V.Am J Hematol. 2020 Jul 6. doi: 10.1002/ajh.25929. Online ahead of print. PMID: 32628327
- The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. Otoukesh S, Zhang J, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V, Aldoss I.Leuk Lymphoma. 2020 Aug;61(8):2020-2023. doi: 10.1080/10428194.2020.1742908. Epub 2020 Mar 19
- Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib. Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S .Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.PMID: 30510081
- Blinatumomab for Acute Lymphoblastic Leukemia Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Stein AS, Kantarjian H, Gökbuget N, Bargou R, Litzow MR, Rambaldi A, Ribera JM, Zhang A, Zimmerman Z, Zugmaier G, Topp MS.Biol Blood Marrow Transplant. 2019 Aug;25(8):1498-1504. doi: 10.1016/j.bbmt.2019.04.010. Epub 2019 Apr 17.PMID: 31002989
- Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia. Aldoss I, Zhang J, Pillai R, Shouse G, Sanchez JF, Mei M, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.Br J Haematol. 2019 Oct;187(2):e45-e48. doi: 10.1111/bjh.16166. Epub 2019 Aug 22.PMID: 31441045
- Transplantation in adults with relapsed/refractory acute lymphoblastic leukemia who are treated with blinatumomab from a phase 3 study. Jabbour EJ, Gökbuget N, Kantarjian HM, Thomas X, Larson RA, Yoon SS, Ghobadi A, Topp MS, Tran Q, Franklin JL, Forman SJ, Stein AS.Cancer. 2019 Dec 1;125(23):4181-4192. doi: 10.1002/cncr.32335. Epub 2019 Aug 21.PMID: 31433496
- Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Aldoss I, Dadwal S, Zhang J, Tegtmeier B, Mei M, Arslan S, Al Malki MM, Salhotra A, Ali H, Aribi A, Sandhu K, Khaled S, Snyder D, Nakamura R, Stein AS, Forman SJ, Marcucci G, Pullarkat V.Blood Adv. 2019 Dec 10;3(23):4043-4049. doi: 10.1182/bloodadvances.2019000930.PMID: 31816059
- A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia. Stein EM, Walter RB, Erba HP, Fathi AT, Advani AS, Lancet JE, Ravandi F, Kovacsovics T, DeAngelo DJ, Bixby D, Faderl S, Jillella AP, Ho PA, O'Meara MM, Zhao B, Biddle-Snead C, Stein AS.Blood. 2018 Jan 25;131(4):387-396. doi: 10.1182/blood-2017-06-789800. Epub 2017 Dec 1.PMID: 29196412
- Acute myeloid leukemia transforms the bone marrow niche into a leukemia-permissive microenvironment through exosome secretion. Kumar B, Garcia M, Weng L, Jung X, Murakami JL, Hu X, McDonald T, Lin A, Kumar AR, DiGiusto DL, Stein AS, Pullarkat VA, Hui SK, Carlesso N, Kuo YH, Bhatia R, Marcucci G, Chen CC.Leukemia. 2018 Mar;32(3):575-587. doi: 10.1038/leu.2017.259. Epub 2017 Aug 1
Ratings and reviews below are gathered from the Press Ganey Clinician and Group Consumer Assessment of Healthcare Providers and Systems (CG CAHPS) survey. CG CAHPS is a standardized survey that is used to measure a patient's experience in the physician office setting. Ratings are an average of all responses to questions about a provider's care, with five stars being the highest.
Ratings
5.0
Provider explain in way you understand
5.0
Provider listen carefully to you
4.9
Know important info medical history
4.9
Show respect for what you say
4.9
Rate provider 0-10
4.9
Recommend this provider office
4.8
Spend enough time with you
Reviews
04/22/23
City of Hope is the best medical facility I have been to. Top notch care!! - Verified patient
04/19/23
Everyone at City of Hope is kind and respectful. - Verified patient
02/23/23
I highly recommend Dr Stein. He continuously provides excellent care. - Verified patient
02/15/23
Good - Verified patient
07/03/22
Love Dr Stein. Been seeing him almost 30 years. - Verified patient